In Response to Continued Growth, Simulab Corporation Adds Salmonsen to the Leadership Team SEATTLE, WASHINGTON / ACCESS ...

Cracking the Code on Interoperability with Scalable, Vendor-Neutral Architectures Powering AI-Ready Health Systems Worldwide ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

Annual Report/Annual ResultsAPONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned 31.03.2025 / 14:00 CET/CESTThe issuer is solely ...

Received positive feedback on New Drug Application submission via the 505(b)(2) pathway-Company leveraging existing human pharmacokinetic data with TH104-Advancing CMC plan to meet requirements of a ...

The Company Successfully Reaches the Second Milestone of ARPA-H $10 Million Award  AUSTIN, TX / ACCESS Newswire / March 31, 2025 / Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical ...

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for ...

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...

Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26Quarterly Adjusted EBITDA ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

A breakthrough in respiratory diagnostics is set to transform the way serious lung conditions, such as Chronic Obstructive Pulmonary Disease (COPD), are detected and managed in the UK.